Kadimastem To Begin Human Trials For ALS Treatment

April 12, 2015 | The Israeli biotechnology company Kadimastem announced that it plans to begin human trials for its stem-cell ALS treatment in the second-half of 2016. The announcement follows an impressive 24-hour approval from the FDA to move forward with the clinical trial process that resulted from the publication of the company’s pre-clinical findings. Kadimastem was founded in 2009 and is headquartered in Ness Ziona, Israel.